#	Pagina
attuale pagina	/open-h2020/projects/195737/index.html

Opendata, web and dolomites

RECOLOR SIGNED

Regulation and consequences of LRRK2 phosphorylation,a path to Parkinson’s disease therapy and diagnostics

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

RECOLOR project word cloud

Explore the words cloud of the RECOLOR project. It provides you a very rough idea of what is the project "RECOLOR" about.

inserm therapeutic signalling protein models reveal health excellence fertile shown university neurodegenerative tau parkinson internationally biology samples follow clinical locally community papers ground performed chosen biomarkers jpa therapy expertise pursuing incurable neurodegeneration disorder phosphorylation exploited verify biosample understand lrrk2 profile disease hospital movement collaborating regulation diagnostic repeat network phosphatases downstream pathogenesis biosamples molecular phenotypes transcriptome profiling modifying fellowship coordinated adding lille neurobiologist experimental leverage france dimension extensive player mixed strategically elucidate visibility builds kinase mechanisms reposition center diseases leucine pd 24 translation host functions groups training cellular international

Project "RECOLOR" data sheet

The following table provides information about the project.

Coordinator	UNIVERSITE DE LILLE II - DROIT ET SANTE Organization address address: RUE PAUL DUEZ 42 city: Lille postcode: 59800 website: www.univ-lille2.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	France [FR]
Project website	http://www.lrrk2.info
Total cost	185˙076 €
EC max contribution	185˙076 € (100%)
Programme	1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
Code Call	H2020-MSCA-IF-2014
Funding Scheme	MSCA-IF-EF-ST
Starting year	2015
Duration (year-month-day)	from 2015-06-01 to 2017-05-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	UNIVERSITE DE LILLE II - DROIT ET SANTE UNIVERSITE DE LILLE II - DROIT ET SANTE Organization address address: RUE PAUL DUEZ 42 city: Lille postcode: 59800 website: www.univ-lille2.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (Lille)	coordinator	185˙076.00

Map

Project objective

Parkinson’s disease (PD) is the most common neurodegenerative movement disorder, currently incurable. Studies in the PD field show that leucine-rich repeat kinase 2 (LRRK2) is both a major player in PD pathogenesis and a promising PD therapeutic target. LRRK2 functions in health and disease are not defined; however the applicant and others have shown that LRRK2 phosphorylation is the key to understanding LRRK2 biology. This project’s goal is therefore to understand the role of LRRK2 phosphorylation in PD by pursuing 3 specific aims: 1) elucidate the regulation of LRRK2 phosphorylation by phosphatases, 2) determine LRRK2 phosphorylation downstream phenotypes in cellular models through transcriptome profiling, protein translation profiling and protein tau related phenotypes, and 3) verify these findings from experimental models in PD biosamples. The project builds on the applicant’s extensive expertise in the field of LRRK2 biology (24 papers in 8 years) required for aim 1 and will leverage expertise on PD biosample analysis of the host institution (training for aims 2 and 3). The research program will be performed at the JPA research center (a mixed Inserm-Lille 2 University-Lille University Hospital center for excellence research, Lille, France), with a network of strategically chosen collaborating research groups locally and internationally, coordinated by the applicant. The study of LRRK2 phosphorylation in experimental models and translation of experimental results to clinical samples will reveal the most relevant molecular mechanisms of LRRK2 in PD which can be exploited in follow up work as diagnostic biomarkers and targeted for disease-modifying therapy. Given the importance of PD and neurodegeneration in Europe, this project is fertile ground for a high visibility fellowship and will reposition the applicant in the international neurodegenerative diseases research community by adding a clinical translation dimension to his signalling neurobiologist profile.

Publications

List of publications.
year	authors and title	journal	last update
2017	Kushal Sejwal, Mohamed Chami, HervÃ© RÃ©migy, RenÃ©e Vancraenenbroeck, William Sibran, Rosmarie SÃ¼tterlin, Paul Baumgartner, Robert McLeod, Marie-Christine Chartier-Harlin, Veerle Baekelandt, Henning Stahlberg, Jean-Marc Taymans Cryo-EM analysis of homodimeric full-length LRRK2 and LRRK1 protein complexes published pages: 8667, ISSN: 2045-2322, DOI: 10.1038/s41598-017-09126-z	Scientific Reports 7/1	2019-06-17
2016	Jean-Marc Taymans, Elisa Greggio LRRK2 Kinase Inhibition as a Therapeutic Strategy for Parkinson\'s Disease, Where Do We Stand? published pages: 214-225, ISSN: 1570-159X, DOI: 10.2174/1570159X13666151030102847	Current Neuropharmacology 14/3	2019-06-17
2017	Jean-Marc Taymans, EugÃ©nie Mutez, Matthieu Drouyer, William Sibran, Marie-Christine Chartier-Harlin LRRK2 detection in human biofluids: potential use as a Parkinson\'s disease biomarker? published pages: 207-212, ISSN: 0300-5127, DOI: 10.1042/BST20160334	Biochemical Society Transactions 45/1	2019-06-17

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RECOLOR" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RECOLOR" are provided by the European Opendata Portal: CORDIS opendata.